Group items tagged

Eczema (atopic dermatitis), which affects up to 20 per cent of children, is one of the most common conditions pharmacists encounter, but don't underestimate eczema. Generalised eczema may compromise health-related quality of life (HRQoL) more than several other chronic diseases, including asthma, epilepsy and diabetes. Despite the impact on HRQoL, underuse of moisturisers and topical corticosteroids often leaves childhood eczema poorly controlled. UK researchers recently reported that several factors contribute to the underuse of moisturisers and topical corticosteroids in children with eczema. For instance, most of the 30 parents and carers interviewed felt that they had received little information about eczema. The lack of understanding may help explain why some parents and carers expressed concerns, such as the risk of skin thinning, about topical corticosteroids. Some were not convinced that moisturisers (strictly, an emollient is an ingredient of a moisturiser) reduced itch and maintained control of eczema. Some felt that moisturisers' efficacy declined over time. Parents and carers also admitted to "incomplete knowledge and skills" about managing eczema (such as whether they should apply moisturisers regularly) and reluctance to manage eczema in collaboration with their child. Parents and carers wanted advice about using treatments and explanations of moisturisers' and topical corticosteroids' mechanisms of action. The authors note that healthcare professionals could help identify and address gaps in knowledge.

The Royal Pharmaceutical Society (RPS) and Pharmacist Support have announced a formal agreement aimed at enhancing collaboration to better support RPS members and increase the impact of the charity. This partnership comes after years of working closely together, and formalising it will allow both organisations to reach a wider audience and focus on supporting the wellbeing of pharmacy professionals. The aim of the partnership is to establish a visible link between the professional body and the independent charity to increase awareness about the two organisations for greater focus on the support within the sector. Along with this, the key objectives also include identifying fundraising opportunities for Pharmacist Support, and collaborating on specific wellbeing projects.

In a significant uptick reflecting growing awareness and acceptance of mental health challenges among new and expectant mothers, NHS records reveal a striking surge in specialist support sought by over 57,000 new mothers over the past year. This figure represents a substantial 33 per cent increase compared to the 2022 data findings indicating a heightened demand for perinatal mental health services in England. Last year, the number of women accessing perinatal mental health services was 43,053 individuals. Specifically, between March 2023 and February 2024, a total of 57,170 women accessed these services, representing a significant rise from the 43,053 women who received support between March 2022 and February 2023. Contextually, this surge in demand is significant given that approximately 600,000 women give birth in England each year.

Kanabo Group plc, a medical cannabis research and development company, has entered into a partnership with City Dock Pharmacy in London to introduce a walk-in clinic for pain management. The pain clinic will cater to patients who are eligible for alternative therapies (when traditional treatments have failed to deliver improvements), and will offer specialised medicines, including medicinal cannabis. When it opens, the new facility at City Dock Pharmacy in Wapping will become the UK's first walk-in clinic for pain management, but it will also deliver appointment-related services, the companies said. The partnership is part of the London-based company's wider ambition to extend its reach into physical pharmacies throughout the UK, and its plans to replicate this model across other pharmacies.

Community Pharmacy England (CPE) has launched its third annual Pressures Survey to uncover the various challenges encountered by individuals owning or working in a community pharmacy. The Committee expressed concern that community pharmacies in England are now in a critical situation, significantly affecting workload, stress levels, patients, and businesses. The 2024 Pharmacy Pressures Survey is aimed at finding out more about these issues and other areas such as medicines supply problems and workforce challenges as well as the recently launched Pharmacy First service, it said. CPE chief executive Janet Morrison said that they were able to receive a huge number of responses in previous surveys and they are expecting to achieve a similar level of engagement this year too.

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition. The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services. The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand. Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.